These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
301 related items for PubMed ID: 29776990
1. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM. Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007394. PubMed ID: 29776990 [Abstract] [Full Text] [Related]
2. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM. J Am Acad Dermatol; 2019 Oct; 81(4):923-930. PubMed ID: 31163241 [Abstract] [Full Text] [Related]
3. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Circ Cardiovasc Imaging; 2013 Jan 01; 6(1):83-90. PubMed ID: 23204039 [Abstract] [Full Text] [Related]
11. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960 [Abstract] [Full Text] [Related]
12. 18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: A randomized placebo-controlled pilot study. Kaur S, Shafiq N, Dogra S, Mittal BR, Attri SV, Bahl A, Narang T, Vinay K, Rajagopalan S, Malhotra S. Indian J Dermatol Venereol Leprol; 2018 Jun 01; 84(6):660-666. PubMed ID: 29893297 [Abstract] [Full Text] [Related]
13. TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, Maari C, Delorme I, Lynde CW, Tardif JC. J Invest Dermatol; 2017 Aug 01; 137(8):1638-1645. PubMed ID: 28286061 [Abstract] [Full Text] [Related]
14. Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, Ng Q, Joshi AA, Krishnamoorthy P, Dave J, Rose SM, Doveikis J, Playford MP, Prussick RB, Ehrlich A, Kaplan MJ, Lockshin BN, Gelfand JM, Mehta NN. Arterioscler Thromb Vasc Biol; 2015 Dec 01; 35(12):2667-76. PubMed ID: 26449753 [Abstract] [Full Text] [Related]
16. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W. Am J Clin Dermatol; 2016 Feb 01; 17(1):79-86. PubMed ID: 26547918 [Abstract] [Full Text] [Related]
17. Vascular Inflammation Evaluated by [18F]-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Is Associated With Endothelial Dysfunction. Honda A, Tahara N, Nitta Y, Tahara A, Igata S, Bekki M, Nakamura T, Sugiyama Y, Kaida H, Kurata S, Fujimoto K, Abe T, Enomoto M, Adachi H, Narula J, Yamagishi S, Fukumoto Y. Arterioscler Thromb Vasc Biol; 2016 Sep 01; 36(9):1980-8. PubMed ID: 27386941 [Abstract] [Full Text] [Related]
18. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT. Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, Ko HC, Kim MB, Kim SJ. J Am Acad Dermatol; 2019 May 01; 80(5):1322-1331. PubMed ID: 29559399 [Abstract] [Full Text] [Related]
19. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. N Engl J Med; 2015 Jul 09; 373(2):136-44. PubMed ID: 26154787 [Abstract] [Full Text] [Related]
20. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA. J Eur Acad Dermatol Venereol; 2015 Oct 09; 29(10):1995-2001. PubMed ID: 25823684 [Abstract] [Full Text] [Related] Page: [Next] [New Search]